ETON PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
ETON PHARMACEUTICALS INC. - More news...
ETON PHARMACEUTICALS INC. - More news...
- Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
- Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
- Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024
- Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
- Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
- Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results
- Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
- Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
- Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results
- Eton Pharmaceuticals to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
- Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection
- Eton Pharmaceuticals Reports First Quarter 2023 Financial Results
- Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution, a Generic Version of Cystadane® (betaine anhydrous for oral solution)
- Eton Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
- Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial Results
- Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600
- Eton Pharmaceuticals to Report Fourth Quarter 2022 Financial Results on Thursday, March 16, 2023
- Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection
- Eton Pharmaceuticals to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
- Eton Pharmaceuticals to Present at the LD Micro Main Event XV Conference
- Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution
- Eton Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
- Eton Pharmaceuticals Reports Second Quarter 2022 Financial Results
- Eton Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
- Eton Pharmaceuticals Announces FDA Approval of ZONISADE™ (Zonisamide Oral Suspension)
- Eton Pharmaceuticals Announces Sale of Hospital Products
- Eton Pharmaceuticals Reports First Quarter 2022 Financial Results
- Eton Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
- Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer